<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01527669</url>
  </required_header>
  <id_info>
    <org_study_id>201110011MB</org_study_id>
    <nct_id>NCT01527669</nct_id>
  </id_info>
  <brief_title>The Pharmacokinetic Study of Red Yeast Rice Capsule Compared to Lovastatin Tablet in Healthy Subjects</brief_title>
  <official_title>The Pharmacokinetic Study of Red Yeast Rice Capsule Compared to Lovastatin Tablet in Healthy Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Science Council, Taiwan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to evaluate the pharmacokinetics of lovastatin and lovastatin&#xD;
      acid of four 600 mg LipoCol Forte capsules compared to that of one 20 mg lovastatin Tablet&#xD;
      after single oral administration in healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is two-ways crossover design. The subjects will receive a dose of four 600 mg&#xD;
      LipoCol Forte Capsules or 20 mg Mevacor Tablet in fasted state in the morning. There is a&#xD;
      minimum of a 6-days washout period before crossover of treatments.&#xD;
&#xD;
      Each subject will be admitted before administration of the investigational product in each&#xD;
      period. Study responsible personnel will give the subjects a single tablet or four capsules&#xD;
      in fasted state in the morning. The blood samples will be drawn prior to the dosing, and&#xD;
      0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8 and 12 hours after the dosing.&#xD;
&#xD;
      Observations will be conducted up to 12 hours after the dosing. If no particular health&#xD;
      abnormalities are observed in each period, the subjects will be discharged on 12 hours after&#xD;
      the dosing.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of the pharmacokinetic parameters of lovastatin and lovastatin acid in healthy subjects</measure>
    <time_frame>1 weeks</time_frame>
    <description>Plasma concentrations of lovastatin and lovastatin acid were detected at following time: (Pre-dose (T0), and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours after oral administration red yeast rice capsule (LipoCol Forte)or lovastatin. All pharmacokinetic parameters were determined with lovastatin and lovastatin acid concentrations by non-compartment methods.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence rate of adverse event</measure>
    <time_frame>1 weeks</time_frame>
    <description>The incidence rate of adverse event</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>LipoCol Forte capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The pharmacokinetic study of red yeast rice capsule compared to lovastatin tablet in healthy subjects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lovastatin Tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The pharmacokinetic study of red yeast rice capsule compared to lovastatin tablet in healthy subjects.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LipoCol Forte capsules</intervention_name>
    <description>The pharmacokinetic study of red yeast rice capsule compared to lovastatin tablet in healthy subjects.</description>
    <arm_group_label>LipoCol Forte capsules</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lovastatin Tablet</intervention_name>
    <description>The pharmacokinetic study of red yeast rice capsule compared to lovastatin tablet in healthy subjects.</description>
    <arm_group_label>Lovastatin Tablet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects must be at the age of 20-40 years old and be able to sign informed consent&#xD;
             prior to study.&#xD;
&#xD;
          2. Body weight must be above 45 kilograms (kg) and within -20 to +20% of ideal body&#xD;
             weight.&#xD;
&#xD;
          3. No clinically significant abnormalities were judged by the principal investigator&#xD;
             based on the medical history, physical examination, electrocardiogram, chest X-ray,&#xD;
             and routine laboratory evaluations.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Use of any prescription medication, over-the-counter medications or vitamins within 14&#xD;
             days prior to dosing.&#xD;
&#xD;
          2. Participation in any clinical investigation within 2 months prior to dosing or longer&#xD;
             as required by local regulation.&#xD;
&#xD;
          3. Donation or loss of more than 500 milliliter (mL) blood within 3 months prior to&#xD;
             dosing.&#xD;
&#xD;
          4. Presence of liver disease (Glutamic Oxaloacetic Transaminase (GOT), Glutamic Pyruvic&#xD;
             Transaminase (GPT) or Total-bilirubin greater than 2-fold normal values) or renal&#xD;
             disease (blood urea nitrogen (BUN) or creatinine greater than 1.5-fold normal values).&#xD;
&#xD;
          5. Creatine kinase (CK) value greater than 1.5-fold normal value.&#xD;
&#xD;
          6. A known hypersensitivity to statins or their analogs.&#xD;
&#xD;
          7. Permanent confinement to an institution.&#xD;
&#xD;
          8. Individuals are judged by the investigator or co-investigator to be undesirable as&#xD;
             subjects for other reasons.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jyh-Chin Yang, M.D. Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <study_first_submitted>January 12, 2012</study_first_submitted>
  <study_first_submitted_qc>February 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2012</study_first_posted>
  <last_update_submitted>July 9, 2012</last_update_submitted>
  <last_update_submitted_qc>July 9, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 11, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Red yeast rice</keyword>
  <keyword>lovastatin</keyword>
  <keyword>Pharmacokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lovastatin</mesh_term>
    <mesh_term>L 647318</mesh_term>
    <mesh_term>Dihydromevinolin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

